VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Paint relief: “The joy of painting outshines my Parkinson’s symptoms”
Self-taught artist Walter Reynecke on how painting calms his condition
6 days ago
Michael J Fox Foundation raises $1m on #GivingTuesday
The Michael J Fox Foundation for Parkinson’s Research raised $1 million on #GivingTuesday – 28 November – as part of their #1Day1million fundraising campaign. The charity had pledged to match-fund any donation up to the one million dollar mark, with 89 cents from every dollar spent at The Foundation going directly to research programmes. In a statement, the organisation said: “We did it: thanks to your support and energy, we met our Giving Tuesday goal of raising $1 million in one day, to help speed a cure for Parkinson’s disease. “Thousands of friends and followers shared their dedication to fuelling Parkinson’s research, championed our mission online, and most critically, donated. It was incredible to see the outpouring of support for the Parkinson’s community, demonstrating how together, we can – and we will – cure Parkinson’s disease.”
Environment and genetics could be key factors in causing Parkinson’s
A recent study by The Scripps Research Institute, in the journal ‘Cell Reports’, shows how a process in nerve cells called the S-nitrosylation (SNO) reaction – which can be caused by ageing, pesticides and pollution – may contribute to Parkinson’s disease. Previous studies had shown that inherited mutations to the gene PINK1 could cause young-onset Parkinson’s. Professor Stuart Lipton, clinical neurologist at the University of California, San Diego, School of Medicine, said: “The new finding gives us a clue as to where to intervene. “The Formation of PINK-SNO is definitely harmful to nerve cells in the Parkinson’s brain.” Lipton’s team found that ‘SNO-ing’ appears to occur early in disease progression – early enough that intervention may be able to save brain function. Professor Lipton continued: “The take-home message here is that the environment may affect you based on your individual genetics, and thus both are influential in causing diseases like Parkinson’s.”
Applications open for MJFF grant to train new movement disorder fellow
Academic institutions are being invited to apply for the 2018 Edmond J Safra Fellowship in Movement Disorders grant awarded by the Michael J Fox Foundation, which will fund the training of a new movement disorder fellow over a two-year period. The grant is open to institutions worldwide, including centres that have previously been awarded. The demand for movement disorder specialists – neurologists with subspecialty training in treating Parkinson’s and other movement disorders – is increasing, but not enough neurologists are receiving this vital specialist training. The Michael J Fox Foundation, in collaboration with long-time supporter and partner the Edmond J Safra Foundation, introduced the scheme to develop a network of highly trained clinician-researchers – the next generation of leaders in Parkinson’s drug development and expert clinical care. The application deadline is 6 December 2017.